EDIT — Editas Medicine, Inc.

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$255.4M

P/E Ratio

-1.45

Beta

2.19

52-Week Range

0.91-4.537

Dividend Yield

$0.00

CEO

Gilmore O'Neill

Employees

246

IPO Date

Feb 3, 2016

Exchange

NASDAQ